Use and misuse of control strains for genetically hypertensive rats.

THE article by Kurtz and Morris 1 in this issue of Hypertension raises important issues with regard to the use of genetically hypertensive rats. These issues are 1) the origins of various stocks, 2) the definition and maintenance of the integrity of various stocks of interest in hypertension research, and 3) the construction, appropriateness, and use of control strains for comparison with hypertensive strains. The article by Kurtz and Morris traces the tortured origin of the Wistar-Kyoto (WKY) "strain" as a control for spontaneously hypertensive rats (SHR); clearly, the need for a control strain here was an afterthought and not all WKY are likely to be genetically identical. Their article illustrates the frustration of leaving unanswered the question of how to obtain genetic information from a hypertensive strain. The problems relating to control strains originate, in my view, from the unrealistic and inappropriate expectations imposed on a comparison of a hypertensive and control strain rather than from the undefined origins and possible genetic inappropriateness of controls. It is obvious from the literature on SHR that many investigators compare SHR and WKY for some biochemical or physiological trait (call it "trait X") and then conclude that the strain difference in trait X may be causally related to blood pressure differences. The problem is that, with this kind of information, the strain difference in trait X may be the result (rather than the cause) of strain differences in blood pressure, or strain differences in trait X may be due to genetic drift. Genetic drift is the chance selection and fixation of the contrasting genes controlling trait X in the two different strains. Strain differences arising from genetic drift have nothing to do with strain differences in blood pressure.